These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16054632)

  • 21. Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Didangelos TP; Peletidou A; Kleta D; Karagiannis A; Kakafika AI; Tziomalos K; Elisaf M
    Metabolism; 2005 Aug; 54(8):1065-74. PubMed ID: 16092057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
    Athyros VG; Katsiki N; Karagiannis A
    Curr Med Res Opin; 2013 Jul; 29(7):791-2. PubMed ID: 23672630
    [No Abstract]   [Full Text] [Related]  

  • 23. Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens.
    Bulut D; Hanefeld C; Bulut-Streich N; Graf C; Mügge A; Spiecker M
    Cardiology; 2005; 104(4):176-80. PubMed ID: 16155389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Inflammation study in unstable angina and myocardial infarction without ST segment elevation. Value of ultra-sensitive C-reactive protein].
    Borrás Pallé S; Gómez Martínez E; Romero Rodrigo A; Campos Ferrer C; Molina E; Valentín Segura V
    An Med Interna; 2002 Jun; 19(6):283-8. PubMed ID: 12152386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular risk and possibilities of lowering it in patients with metabolic syndrome and type II diabetes mellitus. The role of fibrates].
    Konstantinov VO; Saĭfulina IaR
    Kardiologiia; 2006; 46(11):86-91. PubMed ID: 17183753
    [No Abstract]   [Full Text] [Related]  

  • 27. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men.
    Wannamethee SG; Lowe GD; Shaper AG; Rumley A; Lennon L; Whincup PH
    Atherosclerosis; 2005 Jul; 181(1):101-8. PubMed ID: 15939060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome.
    Gao XR; Adhikari CM; Peng LY; Guo XG; Zhai YS; He XY; Zhang LY; Lin J; Zuo ZY
    J Pharm Pharmacol; 2009 Nov; 61(11):1505-10. PubMed ID: 19903376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome.
    Mertens I; Verrijken A; Michiels JJ; Van der Planken M; Ruige JB; Van Gaal LF
    Int J Obes (Lond); 2006 Aug; 30(8):1308-14. PubMed ID: 16389265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Hérnandez G; Egido J;
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):168-74. PubMed ID: 17053166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do we need to consider inflammatory markers when we treat atherosclerotic disease?
    Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
    Atherosclerosis; 2008 Sep; 200(1):1-12. PubMed ID: 18420211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
    Arca M; Cambuli VM; Montali A; Sentinelli F; Filippi E; Campagna F; Quagliarini F; Antonini R; Romeo S; Baroni MG
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):660-6. PubMed ID: 19632099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
    Fedacko J; Pella D; Jarcuska P; Sabol F; Kmec J; Lopuchovsky T; Merkovska L; Jedlickova L; Janicko M; Sajty M
    Adv Ther; 2013 Jan; 30(1):60-70. PubMed ID: 23328937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atorvastatin + amlodipine: new drug. Just a commercial ploy.
    Prescrire Int; 2007 Jun; 16(89):105. PubMed ID: 17582926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
    Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
    Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical effectiveness of metformin and ramipril combination in complex therapy of patients with metabolic syndrome].
    Savchenko LH; Kaĭdasheva EI; Kutsenko LO; Kutsenko NL; Hordyns'ka IL; Mamontova TV; Markina TM; Kaĭdashev IP
    Lik Sprava; 2013; (1):109-17. PubMed ID: 23951921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
    Krysiak R; Gdula-Dymek A; Okopien B
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):198-202. PubMed ID: 22935083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein, inflammation, and cardiovascular disease: clinical update.
    Ridker PM
    Tex Heart Inst J; 2005; 32(3):384-6. PubMed ID: 16392225
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.